TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company, is set to participate in the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. This summit offers unique tax advantages for attendees, aimed at enhancing their investment strategies. Keynote panels and training sessions will be led by industry experts, covering the latest trends and best practices.

On April 26, at 11:00 am ET, TC BioPharm management will present on Track 2. The company's focus is on developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials targeting acute myeloid leukemia. TC BioPharm is recognized for its allogeneic approach and maintains a robust patent portfolio in this innovative field.

The report titled "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" highlights the emerging potential of CD276 immune checkpoint inhibitors in cancer treatment. It forecasts a market value exceeding US$ 1 Billion by 2028, with initial sales of approved therapies projected between US$ 100 Million and US$ 150 Million within their first year. Currently, over 30 drugs are in clinical trials targeting CD276, with various pharmaceutical companies, including Daiichi Sankyo, pursuing innovative treatments. Though no FDA-approved CD276 therapies exist, promising early results from clinical studies indicate significant market opportunities ahead.

TC BioPharm (NASDAQ: TCBP) announced the closure of a public offering, issuing 3,437,500 American Depositary Shares (ADSs), priced at $1.60 each, raising approximately $5.5 million. This includes Series C warrants exercisable at $1.75 per ADS. The funding is intended to extend the company's cash runway through the US FDA IND filing. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering, filed with the SEC on March 27, 2023. TC BioPharm specializes in gamma-delta T cell therapies for cancer, leading pivotal clinical studies in oncology.

TC BioPharm (NASDAQ: TCBP) announced the pricing of a public offering of 3,437,500 American Depositary Shares (ADSs) at $1.60 each, aiming to raise $5.5 million before expenses. The offering, expected to close on or about March 30, 2023, includes Series C warrants with an exercise price of $1.75 per ADS. Proceeds will support working capital and corporate purposes. Additionally, existing warrants for 2,800,000 ADSs issued in November 2022 will be amended to reduce exercise price to $1.75 upon closing. The registration statement was effective as of March 27, 2023.

TC BioPharm (NASDAQ: TCBP) has announced a corporate restructuring aimed at reducing overhead and extending its cash runway. The company plans to cut its workforce by up to 30%, with an expected annual cost saving of over $3 million. This restructuring aligns with TC BioPharm's strategic focus on advancing its lead therapeutic program, TCB-008, and other clinical trials. The CEO emphasized the necessity of these changes to ensure the company's long-term sustainability amid challenging market conditions. The company is also exploring non-dilutive funding options and strategic partnerships to bolster its operations.

TC BioPharm (NASDAQ: TCBP) announced it has received an extension from the Nasdaq Hearings Panel to regain compliance with Listing Rule 5550(b)(2). The company must meet specific milestones by June 30, 2023, which include maintaining a market value of at least $35 million, or alternatively, $2.5 million in shareholders' equity or $500,000 in net income. This extension allows TCBP's stock to continue trading on the Nasdaq Capital Market. TC BioPharm focuses on developing gamma-delta T cell therapies for cancer, being a leader in this field with ongoing clinical trials for its OmnImmune® treatment.

TC BioPharm (NASDAQ: TCBP) announced a strategic shift toward FDA trials for its TCB-008 therapy targeting acute myeloid leukemia (AML). The company plans to submit a protocol for a Phase 1b safety trial in Q3 2023, followed by additional IND submissions by early 2024. The study aims to include approximately 9 patients, focusing on dose escalation. CEO Bryan Kobel emphasized the importance of U.S. trials to align with their long-term goal of becoming a commercial leader in oncology. This approach aims to simplify operations, improve economic efficiency, and leverage the substantial AML patient pool in the U.S., potentially leading to rapid trial enrollment.

TC BioPharm (NASDAQ: TCBP) has appointed Dr. Michael Leek as Chief Technology Officer, resuming operational duties after previously serving as Executive Chairman since June 2021. With over 35 years in cell-based R&D, Dr. Leek co-founded the company in July 2013 and has extensive experience in clinical development. He aims to drive innovation in gamma-delta T cell therapies for cancer treatment, reporting to CEO Bryan Kobel. TCBP leads in developing these therapies and is conducting pivotal clinical trials for its OmnImmune® product in acute myeloid leukemia, utilizing proprietary allogeneic CryoTC technology to supply clinics globally.

On February 21, 2023, TC BioPharm announced the publication of a Phase I trial paper focused on allogeneic γδ T lymphocytes in treating refractory acute myeloid leukemia (AML). Published in a peer-reviewed journal, the study highlights the safety and feasibility of this cell therapy approach. Dr. Emilio Cosimo expressed pride in the research team's work, supporting further research in the area. CEO Bryan Kobel noted the publication as a significant milestone for the company, which is a leader in developing gamma-delta T cell therapies for cancer. TC BioPharm continues to advance its clinical pipeline targeting liquid and solid tumors.